Welcome to our dedicated page for ZIMVIE SEC filings (Ticker: ZIMV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to locate critical details on ZimVie鈥檚 dual dental鈥搒pine operations? Each ZimVie Inc. filing layers FDA clearance updates, clinical trial milestones, and segment revenue splits across hundreds of pages. Sorting through that volume is tough, especially when you simply want to know if a new implant cleared the regulator or how surgeon adoption is trending.
Stock Titan solves that problem. Our AI reads every ZimVie quarterly earnings report 10-Q filing, ZimVie annual report 10-K simplified, and ZimVie 8-K material events explained in real time, then highlights the exact paragraphs on R&D spend, product recalls, and international approvals. Plain-language summaries, ratio snapshots, and risk red-flags mean ZimVie SEC filings explained simply鈥攏o jargon required.
Want transaction insight? Receive instant alerts for ZimVie insider trading Form 4 transactions and track ZimVie executive stock transactions Form 4 before earnings calls. Our coverage extends to:
- Form 4 insider buys & sells with AI commentary on buying patterns
- 10-Q breakdowns that map dental versus spine margins quarter over quarter
- 10-K sections on litigation, FDA risk, and surgeon adoption鈥攁lready summarized
- Proxy statements outlining ZimVie proxy statement executive compensation benchmarks
- AG真人官方-time updates when any new document hits EDGAR
Whether you鈥檙e comparing surface-technology R&D outlays, monitoring cash burn ahead of a product launch, or seeking ZimVie earnings report filing analysis, our AI-powered dashboard lets you focus on decisions, not page counts. Experience understanding ZimVie SEC documents with AI鈥攁nd never miss a ZimVie Form 4 insider transactions real-time update again.
Dynex Capital (DX) has furnished an 8-K solely to make its second-quarter 2025 earnings press release part of the public record. Filed under Item 2.02 on 21 Jul 2025, the report notes that the press release covering results for the period ended 30 Jun 2025 is available on the company鈥檚 website and is attached as Exhibit 99.1. The filing itself contains no revenue, EPS, book value, or guidance figures and discloses no new strategic actions, financings, or risk factors. Other sections comprise routine cover information, securities listings, and exhibit references. Accordingly, the document is procedural and does not, on its own, provide data that would change an investor鈥檚 thesis.
Form 4 highlights for ZimVie Inc. (ZIMV): Senior Vice President and Chief Commercial Officer Indraneel Kanaglekar reported an automatic share disposition on 07/01/2025 related to RSU tax withholding (transaction code F). Exactly 145 common shares were withheld at $9.61 per share to cover taxes upon vesting. Following the transaction, the insider still beneficially owns 62,851 shares, which now include 837 shares purchased through the company鈥檚 ESPP on 05/30/2025. No derivative securities were involved, and there was no open-market sale; the movement is strictly administrative. The filing indicates continued sizeable ownership by the executive, suggesting alignment with shareholders, while the 145-share reduction represents less than 0.25% of the reported holdings and is unlikely to exert market impact.
Insider activity overview: On 07/02/2025 ZimVie Inc. (ZIMV) filed a Form 4 indicating that independent director Richard Kuntz acquired 1,340.909 Deferred Share Units (DSUs) on 06/30/2025 under the company鈥檚 Deferred Compensation Plan for Non-Employee Directors.
鈥� Economic terms: Each DSU is economically equivalent to one share of ZimVie common stock (1-for-1 conversion). The filing lists a reference price of $9.35 but the footnote clarifies the award settles in cash once board service ends.
鈥� Post-transaction holdings: Kuntz now beneficially owns 12,410.656 DSUs; no open-market purchases or sales of common shares were reported. Ownership remains direct, and no derivative instruments with an expiration schedule were created.
鈥� Materiality assessment: The transaction represents routine non-cash director compensation and does not alter ZimVie鈥檚 capital structure or cash flows. Therefore, it is considered neutral for near-term valuation but it modestly aligns director incentives with shareholder performance over time.
FAQ
What is the current stock price of ZIMVIE (ZIMV)?
What is the market cap of ZIMVIE (ZIMV)?
What are ZimVie Inc's core business segments?
How does ZimVie integrate digital technology into its product offerings?
What innovations distinguish ZimVie鈥檚 dental implant solutions?
How does ZimVie address the needs of the spine market?
What role does digital planning play in ZimVie鈥檚 product strategy?
How does ZimVie ensure quality and safety in its products?
What is the significance of ZimVie鈥檚 GenTek restorative portfolio?
How does ZimVie differentiate itself from competitors in its field?
